Connecting to LinkedIn...

W1siziisijiwmtuvmdqvmtuvmdgvntqvmzgvnzi1l01ptlrbu0hfqkxpr19vtljftkrfukvex0lnqudfx3jlc2l6zwrfyw5kx3jlbmrlcmvklmpwzyjdlfsiccisinrodw1iiiwimtkymhgxmjuwiyjdxq

Blog

Lung cancer drug trials to begin for OncoGenex

2/07/2014 by

W1siziisijiwmtqvmtavmjgvmtuvmzqvntevmjq3l2zpbguixsxbinailcj0ahvtyiisijywmhg0mdbcdtawm2uixv0

OncoGenex Pharmaceuticals Inc has said that it is to start new clinical trials investigating the benefits of combining chemotherapy with apatorsen in patients with advanced squamous cell lung cancer. The CedarTM clinical trial is a phase 2 trial that is investigator-sponsored and randomised for sufferers who are yet to have any form of treatment. The majority of treatment for lung cancer currently involves chemotherapy; however, with cancer cells often becoming resistant, it is vital that new methods of preventing this resistance are found to optimise survival rates and increase quality of life for sufferers.

The drug used ‒ in this case apatorsen ‒ is an intravenously delivered pharmaceutical given to patients once a week. It is specifically designed to stop the production of hsp27, a heat shock protein that can enable cancer cells to resist treatments. In phase 2 of the investigation on this experimental drug, 140 patients who currently have stage IV or recurrent squamous cell lung cancers and who have not had any previous treatment will be randomised; as a result, cancer sufferers will receive either gemcitabine and carboplatin therapy, or this same therapy with the addition of apatorsen. The primary objective is to provide people with progression-free survival. Researchers will also evaluate response rates of tumours, safety, health-related quality of life, overall survival and tolerability.

Professor Peter Schmid, the trial’s primary investigator and lead at the Centre for Experimental Cancer Medicine, said: “Despite continuing advances for the treatment of lung cancer, progress in improving survival for patients with squamous cell carcinoma has been particularly slow. Given the depth of preclinical evidence supporting the utility of apatorsen in a broad range of cancers, we are excited to open enrolment in the Cedar trial to shed greater light on the ability of apatorsen to reduce resistance to chemotherapies and improve survival outcomes for patients with squamous cell lung cancer.”

Lung cancer is the world’s most common cancer, with approximately 1.6 million new cases diagnosed every year. It is the leading cause of cancer death for men and women in the United States, accounting for around 160,000 deaths last year. Non-small cell lung cancer currently contributes to around 80% of all lung cancer cases and the vast majority of these are advanced or metastatic at diagnosis. Squamous histology accounts for between 25% and 30% of all lung cancer cases, with chemotherapy remaining the backbone of most treatment plans.

This article was written by Montash.

Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:

ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.

With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.

comments powered by Disqus

Social Stream

Latest News

W1siziisijiwmtcvmdivmtuvmtyvntivmjuvnzkwl2n5ymvyigf0dgfja3muanbnil0swyjwiiwidgh1bwiilcizodb4mtawiyjdxq

UK threatened by serious cyber attacks every ...

2017-02-15 16:00:00 +0000

The security of the UK has been threatened by 188 serious cyber attacks in the last three months, a government security chief has said. National Cyber Security Centre (NCSC) Chief Executive Ciaran Martin told The Sunday Times that national security was put at risk by many of these attacks. Martin was speaking ahead of the official opening of the NCSC, which has been set up to protect critical services in the UK from such attacks and improve underlying i...

W1siziisijiwmtcvmdivmdgvmtavmzcvmzkvnjkyl0n5ymvyifnly3vyaxr5lmpwzyjdlfsiccisinrodw1iiiwimzgwedewmcmixv0

British cyber security workforce rises 163%

2017-02-08 10:00:00 +0000

Data from the UK has shown that the cyber security workforce has grown considerably over the past five years. According to a new report from cyber skills promotion network Tech Partnership, there are now 58,000 more workers in this industry – a rise of 163 per cent. It shows the growing importance of these professionals, with firms across a vast range of industries turning to cyber security specialists to safeguard their data. To collate the report, the...